Tokyo Stock Exchange (TSE) · Basic Materials
Fuso Chemical Co., Ltd. 4368
InterestingScore band: 60–70
The thesis, in one sentence
An exceptional niche chemicals business supplying semiconductor polishing slurry at a very high segment margin, where management's own plan directs nearly all future operating cash flow into capital spending, leaving free cash flow far below the reported figure.
Written for this site in plain English, without figures. The arithmetic is in the full report.
The thesis is from the deep report of 2026-08-25; the verdict badge reflects the latest scoring of 2026-09-06.
Key risks
- Management's own plan absorbs nearly all future cash flow into capital spending
- The multiple sits in the top quartile of its own five-year history
- The growth assumption depends entirely on the artificial-intelligence build-out
What would change the verdict
- Free cash flow yield rises to match the reported figure rather than the plan
- The multiple falls back toward its own five-year median
- Operating margin falls below the tollgate level
- Revenue growth falls below the conservative assumption for two consecutive quarters
Read it yourself
Step five of the method is the reader's: open the latest annual or quarterly report and read it before acting on anything here. A score is a summary, and a summary is not understanding.
This exchange has no stable per-company address, so the link opens the disclosure portal — search there for the ticker.
Next report expected 2026-10-30. The deep report was written against the filings available on 2026-08-25; anything published since is not in it.
Price, one year
DCF valuation range
range of the DCF modelsbase casetoday's price
Valuation range, shape only. Figures in the full version.
Monte Carlo outcome shape
scenarios below today's pricescenarios above today's pricetoday's price
Distribution of simulated outcomes around today's price. Bar heights only; the scale and the percentiles are in the full version.
Chapter one: Executive summary
Deep-value analysis — Fuso Chemical Co., Ltd. (扶桑化学工業), TSE Prime 4368
Analysis date: 08/25/2026 · reference price … (close 08/25/2026, 15:30 JST) · market cap …–323.2 bn · EV … · single currency JPY (flows and price) · analysis, not investment advice.
Fiscal year convention. The fiscal year ends March 31. Throughout this report "FY2026" = the year ended 03/31/2026 (the company calls it 2025年度), "FY2027" = the current year, ending 03/31/2027. The "Leap 2030" plan (飛躍2030) covers FY2027–FY2031 (in the company's notation, 2026–2030年度).
Split adjustment. On 03/30/2026 a 3:1 forward split took place (source: stockanalysis.com/statistics, Stock Splits section, verified 08/25/2026). All per-share figures in this report are post-split. This alone resolves the discrepancy flagged in the research brief (dividend "…" vs "…") — see the "Accounting red flags" chapter, point 6.
Executive summary
The thesis. Fuso Chemical is, almost certainly, the best niche business analyzed in recent months and, at the same time, one of the most expensively priced. The company makes ultra-pure colloidal silica ("Quartron"), the raw material of CMP slurries used to planarize silicon wafers — a critical input, individually qualified at each fab, with a small cost within the customer's structure and catastrophic consequences in case of defect. The electronic materials segment delivered FY2026 revenue of … with an operating margin of 38.3% and an EBITDA margin of 60.2% ("Leap 2030" plan, p. 6, figures in 億円: 415 / 159 / 250). This isn't a chemical manufacturer; it's a tollgate business with a chemical manufacturer's cost structure.
The problem isn't quality, it's the price and the timing of cash flow. At …/share, the stock trades at 18.1× trailing profit (TTM EPS …) and at 19.5× FY2027 guidance profit cleaned of the government subsidy (EPS …). The 5-year P/E band, calculated on 20 quarters from the S&P Global Market Intelligence series, has its median at 13.96× and its historical maximum at 26.61× — so today's price sits in the top quartile of its own valuation history, after a … rise over 52 weeks. P/S is 3.97× against a 5-year median of 2.34×.
The analysis's central finding. The management plan published 05/15/2026 contains a capital-allocation bridge that says, in the company's own numbers, what will be left for the shareholder over the next five years: of … of cumulative operating cash flow (FY2027–FY2031), … go to investment (… maintenance/consolidation, … R&D, … the new Kyoto line, … additional growth investment), … to debt repayment and … to dividends. OUT exactly equals IN. The plan's implicit post-investment free flow is … over five years, i.e. …/year — or …/year after debt repayment — not the … reported as FCF in FY2026. FY2026 was a pause year between two capex programs, not the normal level.
Confirmation already comes from Q1 FY2027: quarterly FCF was −…, net PP&E rose … in a single quarter on paid capex of only …, and "other current liabilities" jumped … — 169 mil off from the PP&E gap. The investment program is running, in commitments, at almost double the payment pace.
Estimated value. I used as the owner-earnings base … — below the FY2026 reported FCF (…), but above the figure implicit in the company's own plan (…/year) — with 8% phase-1 growth, a 9% discount rate (identical to the … WACC S&P Global estimates) and 1.5% terminal growth. Result, triangulated across five models:
| Model | Margin of safety vs … |
|---|---|
| DCF-B bear (OE ×0.85, g1 5%, r 10%, gt 1.0%) | … |
| DCF-B base (OE …, g1 8%, r 9%, gt 1.5%) | … |
| DCF-B bull (OE ×1.15, g1 11%, r 8%, gt 2.0%) | … |
| EPV Greenwald (normalized NOPAT / 9% + net cash) | … |
| 5-year historical multiples (median P/E 13.96× on normalized FY2027 EPS) | … |
Range … … …, median …. The Monte Carlo simulation across 20,000 scenarios gives a median intrinsic value of … and a probability of undervaluation of …%.
Verdict. Excellent business, fortress balance sheet (net cash …, Altman Z 5.74, interest coverage 175×), earnings quality HIGH, but a price that already pays for full execution of the 2030 plan. Not a deep-value position at … Becomes interesting below ~… (the simulation's median intrinsic value) and clearly attractive below ~… a level last reached in December 2025. The divergence from consensus target price (… …, 4 analysts) is the largest in recent analyses and is fully explained by what happens to the cash: consensus values the FY2030 plan profit; I value the cash that reaches the shareholder in the meantime, and the plan says that's nearly zero.
Figures were removed from this excerpt. The full report opens free for five tickers a week — see what's open now.
Full report contents
- Executive summary
- 🔒 The business and the moat (Available in the full report)
- 🔒 Management and capital allocation (Available in the full report)
- 🔒 What changed over the last 4 quarters (Available in the full report)
- 🔒 Balance sheet analysis — Quality of Earnings (Thornton O'Glove method) (Available in the full report)
- 🔒 CEO profile — Outsider traits (William Thorndike method) (Available in the full report)
- 🔒 Accounting red flags (Available in the full report)
- 🔒 Triangulated valuation (Available in the full report)
- 🔒 Pre-mortem (Available in the full report)
- 🔒 Verdict compared with the tracker's GBL score (Available in the full report)
Evaluation history
| Date | Verdict |
|---|---|
| 2026-08-16 | Interesting |
| 2026-08-17 | Interesting |
| 2026-09-06 | Interesting |
Want the rest of this report?
Subscribe to get one full deep report a week by email, the day before it opens on the site.